-
Drug stewardship in chronic kidney disease to achieve effective and safe medication use Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-15 Rasheeda K. Hall, Rümeyza Kazancıoğlu, Teerawat Thanachayanont, Germaine Wong, Dharshana Sabanayagam, Marisa Battistella, Sofia B. Ahmed, Lesley A. Inker, Erin F. Barreto, Edouard L. Fu, Catherine M. Clase, Juan J. Carrero
-
Role of biophysics and mechanobiology in podocyte physiology Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-05 Jonathan Haydak, Evren U. Azeloglu
-
Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-05 Djalila Mekahli, Roman-Ulrich Müller, Matko Marlais, Tanja Wlodkowski, Stefanie Haeberle, Marta López de Argumedo, Carsten Bergmann, Luc Breysem, Carla Fladrowski, Elizabeth P. Henske, Peter Janssens, François Jouret, John Christopher Kingswood, Jean-Baptiste Lattouf, Marc Lilien, Geert Maleux, Micaela Rozenberg, Stefan Siemer, Olivier Devuyst, Franz Schaefer, David J. Kwiatkowski, Olivier Rouvière
-
Innovating dialysis through computational modelling of hollow-fibre haemodialysers Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-04 Ruhit Sinha, Michael V. Rocco, Pirouz Daeihagh, Anne E. Staples
Haemodialyser technology has not advanced much in decades, despite its unresolved shortcomings. Sophisticated new computational tools such as high-fidelity surrogate in silico dialyser models could reduce the time and expense of exploring alternative designs, dialysis dose and operating conditions compared with the current gold standard in vitro studies.
-
Long-term health outcomes associated with hydration status Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-26 Natalia I. Dmitrieva, Manfred Boehm, Paul H. Yancey, Sofia Enhörning
-
The renal glucagon receptor is essential to kidney metabolic and homeostatic functions Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-29 Ellen F. Carney
Kidney glucagon receptors (GCGRs) are expressed along the nephron and downregulated in chronic kidney disease (CKD); however, their physiological functions are not well understood. A study by Philipp Scherer and colleagues provides insights into the roles of GCGRs in normal kidney function and in disease development. The researchers report that adult mice with constitutive or inducible kidney-specific
-
A CAAR NK cell approach to eliminate pathogenic autoantibody-secreting cells Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-28 Ellen F. Carney
Binding of autoantibodies to autoantigens expressed on podocytes causes membranous nephropathy. New findings suggest that chimeric autoantibody receptor (CAAR) natural killer (NK) cells could be used to eliminate pathogenic autoantibody-producing cells in this disease. The researchers conclude that CAAR NK and T cells can eliminate antibody-secreting target cells in an antigen-specific manner, demonstrating
-
Physiological principles underlying the kidney targeting of renal nanomedicines Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-26 Yingyu Huang, Xuhui Ning, Samira Ahrari, Qi Cai, Nilum Rajora, Ramesh Saxena, Mengxiao Yu, Jie Zheng
-
Organ trafficking — a continuing challenge Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-26 Thomas F. Mueller, Sanjay Nagral
Global inequities and inequalities, human and health-care crises, transplantation successes in the face of limited organ availability, and desperate donors and recipients underlie the backstory of organ trafficking, namely the exploitation of the most vulnerable. Despite the framework set out by the Declaration of Istanbul for the ethical donation and transplantation of organs, organ trafficking remains
-
Pericyte–stem cell crosstalk in ccRCC Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-26 Susan J. Allison
The cells that surround tumours can influence tumour growth and response to therapy. In new research, ChuanJie Zhang and colleagues report the identification of a subset of pericytes that sustain the proliferation of cancer stem cells (CSCs) in clear cell renal cell carcinoma (ccRCC) and promote tumour resistance to tyrosine kinase inhibitors (TKIs). PDGFRβ+GPR91+ pericytes, identified by single-cell
-
Sirtuins in kidney health and disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-06 Luca Perico, Giuseppe Remuzzi, Ariela Benigni
-
Macrophages clean out the tubules Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-01 Monica Wang
Urine supersaturation can lead to intraluminal accumulation of mineral crystals and kidney stone formation. A study by Xiao Z. Shen and colleagues now shows how juxtatubular macrophages keep these particles in check.
-
Design of a renal-sparing antifungal Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-30 Susan J. Allison
AmB kills fungi through the formation of large sponge-like aggregates that remove ergosterol from the cell membrane of fungi. However, Arun Maji and colleagues found that as well as removing ergosterol, AmB also removes cholesterol — a sterol that demonstrates similarities to ergosterol and is essential for normal functioning of the cell membrane — from the membranes of kidney cells. A series of investigations
-
Effects of SGLT2 inhibitors on the metabolic environment and uraemic toxins Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-30 Ellen F. Carney
Sodium–glucose co-transporter 2 (SGLT2) inhibitors have kidney and cardiovascular protective effects in individuals with and without diabetes. A multi-omics study provides insights into the mechanisms.
-
A united vision for cardiovascular–kidney–metabolic health Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-29 Susan E. Quaggin, Benjamin Magod
Improved understanding of the interrelated nature of cardiovascular, kidney and metabolic (CKM) health, the development of novel risk prediction equations, and the availability of powerful new therapies provide an opportunity to change the course of CKM health. Achieving such change at a population level will require additional advances to deliver equitable interdisciplinary care.
-
The multifaceted links between hearing loss and chronic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-29 Dina Greenberg, Norman D. Rosenblum, Marcello Tonelli
-
The changing landscape of HIV-associated kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-25 Nina E. Diana, Saraladevi Naicker
-
Amplifying the voices of patients with kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-22 Miranda Scanlon
All patients with kidney disease have the right to have a say in their own clinical care, the provision of health services and research into kidney disease. Patient empowerment and advocacy, especially for those whose views are seldom heard, can be enhanced by working together in communities.
-
Metabolic alterations in hereditary and sporadic renal cell carcinoma Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-22 Nathan J. Coffey, M. Celeste Simon
-
Health policy for universal, sustainable and equitable kidney care Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-18 Ricardo Silvariño, Laura Solá
Treatment of chronic kidney disease requires a comprehensive approach including universal access to early diagnosis and to medications that can slow disease progression. Such equitable access is not only an ethical requirement but can also reduce the financial and human costs of advancing kidney and cardiovascular disease.
-
Overcoming barriers to deliver high quality kidney care Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-11 Adeera Levin
Overcoming barriers to deliver high-quality care requires an assessment of the contribution of each barrier within a local context. Tools to identify early disease, knowledge of best therapies, access to care providers and medications, and an accountable and integrated health-care system are essential elements of quality care. Education of patients, providers and policy makers in conjunction with advocacy
-
Expanding the global nephrology workforce Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-10 Ikechi G. Okpechi, Somkanya Tungsanga, Anukul Ghimire, David W. Johnson, Aminu K. Bello
-
Vascular damage in systemic lupus erythematosus Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-03 William G. Ambler, Mariana J. Kaplan
-
Translating B cell immunology to the treatment of antibody-mediated allograft rejection Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-02 Peter S. Heeger, Maria Carrera Haro, Stanley Jordan
-
New and emerging therapies for diabetic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-02 Ricardo Correa-Rotter, Louise J. Maple-Brown, Rakesh Sahay, Katherine R. Tuttle, Ifeoma I. Ulasi
The theme of World Kidney Day 2024 is “kidney health for all — advancing equitable access to care and optimal medication practice”. To mark this event, Nature Reviews Nephrology invited five researchers from different geographical regions worldwide to discuss the impact of new and emerging therapies for diabetic kidney disease on patient care as well as the barriers that must be overcome to ensure
-
Single-cell genomics sheds light on kidney tissue immunity Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-21 Andrew P. Stewart, Menna R. Clatworthy
-
Reaping the rewards of mechanistic discovery in glomerular disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-20 Arpita Joshi, Laura H. Mariani
-
New evidence of the impact of mitochondria on kidney health and disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-14 Thomas Verissimo, Sophie de Seigneux
-
The dawn of multimodal artificial intelligence in nephrology Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-14 Benjamin Shickel, Azra Bihorac
-
Progress towards improving blood pressure control Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-06 Kate M. Denton
-
Targeted identification of risk and treatment of diabetic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-01 Sarah J. Glastras, Carol A. Pollock
Basic discovery and clinical trials in diabetic kidney disease (DKD) have continued to be reported in 2023 despite the disruption of research activity by COVID-19 in recent years. Advances in clinical trials and emerging ways to diagnose, monitor and treat DKD dominate the current literature.
-
Consideration of sex differences is necessary to achieve health equity Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-30
Improved understanding of the impact of sex and gender-related factors on human health and disease and the inclusion of people of all genders in research studies is necessary to reduce health inequities and enable a more personalized approach to patient care.
-
Renoprotective effects of sparsentan: clinical trial evidence in IgA nephropathy and FSGS Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-27 Monica Wang
In early 2023, the dual endothelin–angiotensin receptor antagonist sparsentan became the first non-immunosuppressive therapy to be approved by the US Food and Drug Administration for the treatment of IgA nephropathy (IgAN), on the basis of data that showed a reduction in proteinuria. Two new clinical trials presented at ASN Kidney Week 2023 further support the renoprotective potential of this therapy
-
Targeting APRIL to slow progression of IgA nephropathy Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-27 Monica Wang
TNF family ligands such as a proliferation-inducing ligand (APRIL) promote B cell expansion and survival. New clinical trial data presented at ASN Kidney Week 2023 suggest that targeting APRIL might be therapeutic in IgA nephropathy (IgAN).
-
Author Correction: The immunoregulatory roles of non-haematopoietic cells in the kidney. Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-23 George C Tsokos,Afroditi Boulougoura,Vivek Kasinath,Yushiro Endo,Reza Abdi,Hao Li
-
Mechanisms and consequences of sex differences in immune responses Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-22 Shannon E. Dunn, Whitney A. Perry, Sabra L. Klein
-
Differences in the epidemiology, management and outcomes of kidney disease in men and women Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-20 Nicholas C. Chesnaye, Juan Jesus Carrero, Manfred Hecking, Kitty J. Jager
-
The immunoregulatory roles of non-haematopoietic cells in the kidney Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-20 George C. Tsokos, Afroditi Boulougoura, Vivek Kasinath, Ushiro Endo, Reza Abdi, Hao Li
-
Kidney xenotransplantation edges closer to the clinic Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-16 Eckhard Wolf, Bruno Reichart
-
Chronic cardiovascular–kidney disorder: a new conceptual framework Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-15 Carmine Zoccali, Francesca Mallamaci, Jean-Michel Halimi, Patrick Rossignol, Pantelis Serafidis, Raffaele De Caterina, Robert Giugliano, Faiez Zannad
-
Publisher Correction: Drosophila melanogaster: a simple genetic model of kidney structure, function and disease. Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-10 Julian A T Dow,Matias Simons,Michael F Romero
-
Sex differences in energy metabolism: natural selection, mechanisms and consequences Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-03 Franck Mauvais-Jarvis
-
Author Correction: Regulatory T cells in autoimmune kidney diseases and transplantation. Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-01 Norihisa Mikami,Shimon Sakaguchi
-
A new pathway links iron sensing with histone demethylation and regulation of mTORC1 activity Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-26 Ellen F. Carney
Various regulatory pathways have evolved to enable cell survival during iron deficiency. However, the mechanisms by which cells sense iron and modulate energy metabolism are unclear. Now, Jason Shapiro and co-authors have identified a new pathway by which eukaryotic cells sense iron and regulate pro-anabolic mTORC1 activity.
-
Clonal haematopoiesis, ageing and kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-26 Caitlyn Vlasschaert, Matthew B. Lanktree, Michael J. Rauh, Tanika N. Kelly, Pradeep Natarajan
-
Taking kidney temperatures to detect rejection Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-25 Monica Wang
Early detection of transplant rejection is crucial to prevent graft loss and might be facilitated by wireless implantable bioelectronic systems, according to a new study by John Rogers and colleagues.
-
Transport and barrier mechanisms that regulate ciliary compartmentalization and ciliopathies Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-23 Ailis L. Moran, Laura Louzao-Martinez, Dominic P. Norris, Dorien J. M. Peters, Oliver E. Blacque
-
Equitable access to kidney transplants for Aboriginal and Torres Strait Islander people in Australia Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-19 Stephen P. McDonald, Katie Cundale, Kelli J. Owen, Matilda D’Antoine, Jaquelyne T. Hughes
-
Oxidative stress and the role of redox signalling in chronic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-19 Seiji Kishi, Hajime Nagasu, Kengo Kidokoro, Naoki Kashihara
-
TRPM channels in health and disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-18 Vladimir Chubanov, Michael Köttgen, Rhian M. Touyz, Thomas Gudermann
-
Embryo complementation to generate a humanized mesonephros in pigs Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-13 Susan J. Allison
The use of embryo complementation to grow human organs in nonhuman mammals, such as pigs, may represent a future source of organs for human transplantation. Jiaowei Wang and colleagues now demonstrate the potential feasibility of this approach through the generation of humanized mesonephroi in nephric-defective pigs using embryo complementation with pluripotent stem cells (PSCs).
-
MSC therapy for diabetic kidney disease and nephrotic syndrome Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-10-02 Bo Lu, Lilach O. Lerman
-
The immune response to pig-to-human kidney xenografts Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-27 Ellen F. Carney
A recent study has characterized the early immune response to xenotransplantation. The researchers used a multimodal approach to phenotype two α-1,3-galactosyltransferase-knockout pig kidney xenografts that were transplanted into brain-dead human recipients. The xenografts remained functional and produced urine throughout the 54-h study period, with no evidence of hyperacute rejection.
-
Acute kidney injury in patients with burns Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-27 Matthieu Legrand, Audra T. Clark, Javier A. Neyra, Marlies Ostermann
-
Biomolecular condensates in kidney physiology and disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-26 Guoming Gao, Emily S. Sumrall, Sethuramasundaram Pitchiaya, Markus Bitzer, Simon Alberti, Nils G. Walter
-
Gene therapy in a model of nephrotic syndrome Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-25 Susan J. Allison
Mutations in NPHS2 — which encodes the slit diaphragm protein, podocin — are the most common genetic cause of steroid-resistant nephrotic syndrome. Using genetic models of nephrotic syndrome, Ding et al. now demonstrate that adeno-associated virus (AAV)-mediated delivery of podocin can rescue defects in NPHS2.
-
The role of complement in kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-21 Vojtech Petr, Joshua M. Thurman
-
Use of kidneys from SARS-CoV-2 infected donors Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-21 Monica Wang
Transplantation of kidneys from donors with detectable SARS-CoV-2 RNA is generally deemed safe. In a new study, Miklos Molnar and colleagues investigated whether transplanting organs from deceased infected donors, including those who died from COVID-19, can affect transplant outcomes.
-
Lymph vessels, Na+ and the teleological science of hypertension Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-15 Jens M. Titze
-
Sex differences in renal transporters: assessment and functional consequences Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-08 Alicia A. McDonough, Autumn N. Harris, Lingyun (Ivy) Xiong, Anita T. Layton